While the reduction in price target from $112 to $108 by Mizuho could be seen as a negative adjustment, the maintenance of a Buy rating by analyst Graig Suvannavejh suggests a continued positive outlook on Axsome Therapeutics. The slight adjustment in price target might reflect recent market conditions or updates in the company's financials or pipeline, but the overall recommendation remains bullish. This could lead to a neutral short-term impact on AXSM's stock price as the market digests the mixed signals of a lower price target with a maintained Buy rating.